| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 30 | 2019 | 458 | 2.150 |
Why?
|
| Breast Neoplasms | 17 | 2019 | 765 | 1.170 |
Why?
|
| Colorectal Neoplasms | 4 | 2020 | 215 | 0.680 |
Why?
|
| Receptor, erbB-2 | 6 | 2019 | 65 | 0.660 |
Why?
|
| Lung Neoplasms | 11 | 2013 | 414 | 0.630 |
Why?
|
| Colonic Neoplasms | 6 | 2018 | 71 | 0.600 |
Why?
|
| Middle Aged | 56 | 2020 | 11839 | 0.500 |
Why?
|
| Adenocarcinoma | 6 | 2015 | 308 | 0.460 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2010 | 101 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2018 | 367 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2019 | 190 | 0.420 |
Why?
|
| Tamoxifen | 6 | 2011 | 59 | 0.400 |
Why?
|
| Aged | 44 | 2020 | 10314 | 0.400 |
Why?
|
| Female | 54 | 2020 | 20015 | 0.380 |
Why?
|
| Disease-Free Survival | 17 | 2019 | 317 | 0.360 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2015 | 42 | 0.360 |
Why?
|
| Ethmoid Sinusitis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Maxillary Sinusitis | 1 | 2010 | 1 | 0.360 |
Why?
|
| Rhinitis | 1 | 2010 | 11 | 0.350 |
Why?
|
| Doxorubicin | 11 | 2019 | 82 | 0.350 |
Why?
|
| Cyclophosphamide | 10 | 2019 | 38 | 0.340 |
Why?
|
| Catheterization | 1 | 2010 | 58 | 0.340 |
Why?
|
| Quality of Life | 11 | 2017 | 946 | 0.330 |
Why?
|
| Aged, 80 and over | 25 | 2018 | 3990 | 0.330 |
Why?
|
| Humans | 59 | 2020 | 32114 | 0.320 |
Why?
|
| Neoplasms | 6 | 2018 | 728 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 7 | 2010 | 246 | 0.300 |
Why?
|
| Adult | 33 | 2018 | 9380 | 0.290 |
Why?
|
| Male | 40 | 2020 | 19217 | 0.280 |
Why?
|
| Treatment Outcome | 20 | 2015 | 3306 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 4 | 2007 | 25 | 0.270 |
Why?
|
| Fatigue | 5 | 2014 | 85 | 0.250 |
Why?
|
| Neoplasm Staging | 13 | 2013 | 447 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2020 | 2283 | 0.240 |
Why?
|
| Drug Administration Schedule | 12 | 2013 | 276 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2009 | 608 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 301 | 0.220 |
Why?
|
| Quinazolines | 3 | 2013 | 38 | 0.220 |
Why?
|
| Patient Selection | 3 | 2010 | 276 | 0.210 |
Why?
|
| Survival Analysis | 10 | 2020 | 483 | 0.200 |
Why?
|
| Paclitaxel | 8 | 2017 | 67 | 0.200 |
Why?
|
| Taxoids | 6 | 2013 | 59 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 154 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2015 | 18 | 0.190 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 24 | 0.180 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2010 | 9 | 0.180 |
Why?
|
| Leukemia | 1 | 2020 | 40 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2013 | 180 | 0.180 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2010 | 36 | 0.180 |
Why?
|
| Deoxycytidine | 5 | 2013 | 68 | 0.170 |
Why?
|
| Nausea | 4 | 2010 | 53 | 0.170 |
Why?
|
| Rural Population | 1 | 2002 | 277 | 0.170 |
Why?
|
| Exercise | 2 | 2019 | 673 | 0.160 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 1 | 0.160 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 9 | 0.160 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2010 | 25 | 0.150 |
Why?
|
| Carboplatin | 8 | 2013 | 48 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 2265 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 114 | 0.150 |
Why?
|
| Mutation | 2 | 2010 | 489 | 0.150 |
Why?
|
| Dietary Fats | 1 | 2018 | 110 | 0.150 |
Why?
|
| Cardiovascular System | 1 | 2017 | 43 | 0.150 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 201 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 130 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 36 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 67 | 0.130 |
Why?
|
| Thromboembolism | 3 | 2010 | 34 | 0.130 |
Why?
|
| Organoplatinum Compounds | 4 | 2010 | 46 | 0.130 |
Why?
|
| Amenorrhea | 2 | 2011 | 4 | 0.110 |
Why?
|
| Yoga | 1 | 2014 | 50 | 0.110 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 113 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2013 | 21 | 0.110 |
Why?
|
| Feces | 1 | 2013 | 38 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 166 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 85 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2020 | 684 | 0.110 |
Why?
|
| Hypertension | 2 | 2018 | 960 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 17 | 0.110 |
Why?
|
| Survival Rate | 5 | 2018 | 877 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 190 | 0.100 |
Why?
|
| Fluorouracil | 5 | 2012 | 81 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 93 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2014 | 270 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2010 | 471 | 0.100 |
Why?
|
| Interferon-alpha | 2 | 2010 | 70 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 3880 | 0.100 |
Why?
|
| Menstruation | 1 | 2011 | 5 | 0.100 |
Why?
|
| ras Proteins | 1 | 2010 | 10 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2020 | 1817 | 0.090 |
Why?
|
| Prognosis | 5 | 2018 | 1497 | 0.090 |
Why?
|
| Factor V | 1 | 2010 | 7 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 18 | 0.090 |
Why?
|
| Maxillary Sinus | 1 | 2010 | 7 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 85 | 0.090 |
Why?
|
| Furans | 1 | 2009 | 3 | 0.090 |
Why?
|
| Ketones | 1 | 2009 | 11 | 0.090 |
Why?
|
| Disease Progression | 4 | 2019 | 594 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2007 | 100 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 47 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2009 | 14 | 0.090 |
Why?
|
| Endoscopy | 1 | 2010 | 58 | 0.090 |
Why?
|
| Neutropenia | 4 | 2013 | 29 | 0.080 |
Why?
|
| Estrogens | 1 | 2010 | 180 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2010 | 131 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2009 | 69 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 134 | 0.080 |
Why?
|
| Leucovorin | 4 | 2010 | 24 | 0.080 |
Why?
|
| United States | 6 | 2019 | 3976 | 0.080 |
Why?
|
| Camptothecin | 4 | 2013 | 51 | 0.080 |
Why?
|
| Awareness | 1 | 2008 | 29 | 0.080 |
Why?
|
| Androstadienes | 1 | 2008 | 17 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2010 | 406 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2010 | 221 | 0.080 |
Why?
|
| Confidence Intervals | 4 | 2013 | 149 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 40 | 0.080 |
Why?
|
| Indoles | 1 | 2008 | 56 | 0.070 |
Why?
|
| Cisplatin | 4 | 2013 | 76 | 0.070 |
Why?
|
| Pyrroles | 1 | 2008 | 55 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 36 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2006 | 8 | 0.070 |
Why?
|
| Pyrazines | 1 | 2006 | 13 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 76 | 0.070 |
Why?
|
| Heart Failure | 1 | 2012 | 639 | 0.070 |
Why?
|
| Time Factors | 5 | 2013 | 2151 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 35 | 0.070 |
Why?
|
| Guanine | 1 | 2005 | 15 | 0.070 |
Why?
|
| Glutamates | 1 | 2005 | 11 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2010 | 1166 | 0.060 |
Why?
|
| Logistic Models | 3 | 2013 | 783 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2013 | 472 | 0.060 |
Why?
|
| Cachexia | 1 | 2004 | 7 | 0.060 |
Why?
|
| Remission Induction | 3 | 2010 | 84 | 0.060 |
Why?
|
| Fish Oils | 1 | 2004 | 36 | 0.060 |
Why?
|
| Mastectomy | 2 | 2015 | 64 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2005 | 80 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2018 | 112 | 0.060 |
Why?
|
| Finasteride | 1 | 2003 | 4 | 0.060 |
Why?
|
| Antiemetics | 1 | 2003 | 6 | 0.060 |
Why?
|
| Vomiting | 1 | 2003 | 24 | 0.060 |
Why?
|
| Serotonin | 1 | 2003 | 38 | 0.050 |
Why?
|
| Cognition | 1 | 2007 | 556 | 0.050 |
Why?
|
| Alprostadil | 1 | 2002 | 3 | 0.050 |
Why?
|
| Misoprostol | 1 | 2002 | 5 | 0.050 |
Why?
|
| Pharynx | 1 | 2002 | 14 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 322 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2013 | 27 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2002 | 20 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 3 | 2007 | 62 | 0.050 |
Why?
|
| Mouth Neoplasms | 1 | 2002 | 18 | 0.050 |
Why?
|
| Mouth Mucosa | 1 | 2002 | 30 | 0.050 |
Why?
|
| African Americans | 1 | 2010 | 1425 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2009 | 220 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2010 | 525 | 0.050 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 72 | 0.050 |
Why?
|
| Canada | 2 | 2013 | 56 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 1189 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 638 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 560 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 261 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 297 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 40 | 0.040 |
Why?
|
| Incidence | 3 | 2010 | 1199 | 0.040 |
Why?
|
| Etoposide | 2 | 2013 | 34 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 86 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 30 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 898 | 0.040 |
Why?
|
| Cataract | 2 | 2010 | 8 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2009 | 187 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 538 | 0.040 |
Why?
|
| Endometrial Neoplasms | 2 | 2010 | 49 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 82 | 0.040 |
Why?
|
| Energy Intake | 1 | 2018 | 128 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 321 | 0.040 |
Why?
|
| Myocardial Ischemia | 2 | 2010 | 107 | 0.040 |
Why?
|
| North Carolina | 1 | 2002 | 1538 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2007 | 93 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 510 | 0.040 |
Why?
|
| Probability | 2 | 2006 | 159 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 170 | 0.030 |
Why?
|
| Cause of Death | 2 | 2008 | 236 | 0.030 |
Why?
|
| Research Design | 2 | 2010 | 315 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 78 | 0.030 |
Why?
|
| Pain | 2 | 2009 | 288 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 547 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2007 | 464 | 0.030 |
Why?
|
| Urination Disorders | 1 | 2015 | 5 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 263 | 0.030 |
Why?
|
| Perineum | 1 | 2015 | 18 | 0.030 |
Why?
|
| Anal Canal | 1 | 2015 | 20 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 12 | 0.030 |
Why?
|
| Body Image | 1 | 2015 | 19 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 633 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 43 | 0.030 |
Why?
|
| Abdomen | 1 | 2015 | 43 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 835 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 881 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 338 | 0.030 |
Why?
|
| Fractures, Bone | 2 | 2006 | 148 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2013 | 11 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 28 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2006 | 185 | 0.030 |
Why?
|
| Esophagitis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Dehydration | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2012 | 9 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 288 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 160 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 175 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vidarabine | 1 | 2010 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 14 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 25 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 35 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fractures, Spontaneous | 1 | 2010 | 16 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2010 | 11 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2006 | 1429 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 107 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 58 | 0.020 |
Why?
|
| Premenopause | 1 | 2010 | 44 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 49 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 73 | 0.020 |
Why?
|
| Uterus | 1 | 2010 | 103 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 780 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 137 | 0.020 |
Why?
|
| Urothelium | 1 | 2009 | 55 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 138 | 0.020 |
Why?
|
| Diarrhea | 1 | 2009 | 60 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 39 | 0.020 |
Why?
|
| Stomatitis | 1 | 2008 | 18 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Perception | 1 | 2008 | 101 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2007 | 28 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 753 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 989 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 294 | 0.020 |
Why?
|
| Topotecan | 1 | 2006 | 17 | 0.020 |
Why?
|
| Levamisole | 1 | 2006 | 2 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2007 | 134 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 78 | 0.020 |
Why?
|
| Thalidomide | 1 | 2006 | 31 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 263 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2006 | 27 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 172 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 10 | 0.020 |
Why?
|
| New York | 1 | 2006 | 21 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 528 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 225 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 111 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 73 | 0.020 |
Why?
|
| Vincristine | 1 | 2005 | 17 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2005 | 70 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2006 | 158 | 0.020 |
Why?
|
| Prealbumin | 1 | 2004 | 9 | 0.020 |
Why?
|
| Capsules | 1 | 2004 | 14 | 0.020 |
Why?
|
| Communication | 1 | 2006 | 142 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2004 | 57 | 0.010 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Weight Gain | 1 | 2004 | 117 | 0.010 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 62 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 98 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2665 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2002 | 2 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 15 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 185 | 0.010 |
Why?
|
| Prostate | 1 | 2003 | 68 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 259 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 1542 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 585 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2005 | 3510 | 0.010 |
Why?
|